oru.sePublikasjoner
Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
The future disease burden of hepatitis C virus infection in Sweden and the impact of different treatment strategies
Örebro universitet, Institutionen för hälsovetenskap och medicin. Region Örebro län. Department of Infectious Diseases, , Örebro University Hospital, Örebro, Sweden.ORCID-id: 0000-0001-7248-0910
Center for Disease Analysis (CDA), Louisville CO, USA.
Department of Medicine Huddinge, Division of Infectious Diseases, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden.
Department of Medicine Huddinge, Division of Infectious Diseases, Karolinska University Hospital, Karolinska Institutet, , Stockholm, Sweden.
Vise andre og tillknytning
2015 (engelsk)Inngår i: Scandinavian Journal of Gastroenterology, ISSN 0036-5521, E-ISSN 1502-7708, Vol. 50, nr 2, s. 233-244Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

Objective: Recently, new highly effective direct-acting antivirals (DAAs) against hepatitis C virus (HCV) were introduced. Whether these will alleviate the anticipated increase of liver disease burden in Sweden is unknown, partly because high costs may restrict the use. The objectives were to model the HCV epidemic in Sweden, the burden of disease, and the potential impact of different treatment strategies.

Material and methods: HCV disease progression was modeled to 2030. Scenarios were simulated using new DAAs with sustained annual treatment rate (n = 1130), reduced treatment rate (n = 380) to maintain budget, and increased treatment rates (n = 1430 or 2260) to reduce HCV infections.

Results: With today's triple therapies, the estimated number of serious liver complications and death are expected to peak in 2021. Using new DAAs among F0-F4 patients, an unchanged annual treatment rate can reduce the number of HCV infections by 10% by 2030; however, hepatocellular carcinoma (HCC) and mortality will remain unchanged. By reducing to 380 treatments annually and focusing on patients with advanced fibrosis (F3-F4), serious complications will remain constant but the total number of HCV infections will increase. By doubling the number of DAA treatments, HCC-incidence and liver-related deaths would decrease by 65-70% by 2030.

Conclusion: Mortality and HCC can be reduced with new DAAs and sustained treatment uptake when restricted to F2-F4 patients, or with increased uptake in F0-F4 patients. Treatment restrictions to limit cost may reduce the positive effects and increase the burden of HCV infection. These results may be important for the future strategies of HCV management.

sted, utgiver, år, opplag, sider
London: Informa Healthcare, 2015. Vol. 50, nr 2, s. 233-244
Emneord [en]
Direct-acting antiviral agents; Epidemiology; Hepatitis C; Hepatitis C virus; Hepatocellular carcinoma; Modeling; Mortality
HSV kategori
Identifikatorer
URN: urn:nbn:se:oru:diva-41031DOI: 10.3109/00365521.2014.990505ISI: 000347692700015PubMedID: 25515032Scopus ID: 2-s2.0-84921323762OAI: oai:DiVA.org:oru-41031DiVA, id: diva2:779399
Merknad

Funding Agency:

Gilead

Tilgjengelig fra: 2015-01-12 Laget: 2015-01-12 Sist oppdatert: 2018-09-14bibliografisk kontrollert

Open Access i DiVA

Fulltekst mangler i DiVA

Andre lenker

Forlagets fulltekstPubMedScopus

Personposter BETA

Duberg, Ann-Sofi

Søk i DiVA

Av forfatter/redaktør
Duberg, Ann-Sofi
Av organisasjonen
I samme tidsskrift
Scandinavian Journal of Gastroenterology

Søk utenfor DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric

doi
pubmed
urn-nbn
Totalt: 510 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf